Literature DB >> 8861914

Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.

T Holtschke1, J Löhler, Y Kanno, T Fehr, N Giese, F Rosenbauer, J Lou, K P Knobeloch, L Gabriele, J F Waring, M F Bachmann, R M Zinkernagel, H C Morse, K Ozato, I Horak.   

Abstract

Interferon consensus sequence binding protein (ICSBP) is a transcription factor of the interferon (IFN) regulatory factor (IRF) family. Mice with a null mutation of ICSBP exhibit two prominent phenotypes related to previously described activities of the IRF family. The first is enhanced susceptibility to virus infections associated with impaired production of IFN(gamma). The second is deregulated hematopoiesis in both ICSBP-/- and ICSBP+/- mice that manifests as a syndrome similar to human chronic myelogenous leukemia. The chronic period of the disease progresses to a fatal blast crisis characterized by a clonal expansion of undifferentiated cells. Normal mice injected with cells from mice in blast crisis developed acute leukemia within 6 weeks of transfer. These results suggest a novel role for ICSBP in regulating the proliferation and differentiation of hematopoietic progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8861914     DOI: 10.1016/s0092-8674(00)81348-3

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  258 in total

1.  IFN consensus sequence binding protein potentiates STAT1-dependent activation of IFNgamma-responsive promoters in macrophages.

Authors:  C Contursi; I M Wang; L Gabriele; M Gadina; J O'Shea; H C Morse; K Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers.

Authors:  A L Brass; A Q Zhu; H Singh
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

3.  Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.

Authors:  N Schöler; K Krause; O Kayser; R H Müller; K Borner; H Hahn; O Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Transcription factor IRF8 plays a critical role in the development of murine basophils and mast cells.

Authors:  Haruka Sasaki; Daisuke Kurotaki; Naoki Osato; Hideaki Sato; Izumi Sasaki; Shin-ichi Koizumi; Hongsheng Wang; Chika Kaneda; Akira Nishiyama; Tsuneyasu Kaisho; Hiroyuki Aburatani; Herbert C Morse; Keiko Ozato; Tomohiko Tamura
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

Review 5.  Transcriptional regulation of myelopoiesis.

Authors:  Alan D Friedman
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

Review 6.  Transcriptional regulation of macrophage polarization: enabling diversity with identity.

Authors:  Toby Lawrence; Gioacchino Natoli
Journal:  Nat Rev Immunol       Date:  2011-10-25       Impact factor: 53.106

Review 7.  Transcriptional programming of the dendritic cell network.

Authors:  Gabrielle T Belz; Stephen L Nutt
Journal:  Nat Rev Immunol       Date:  2012-01-25       Impact factor: 53.106

8.  ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines.

Authors:  Valentina Nardi; Olaia Naveiras; Mohammad Azam; George Q Daley
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

9.  Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis.

Authors:  Shreeram C Nallar; Sudhakar Kalakonda; Daniel J Lindner; Robert R Lorenz; Eric Lamarre; Xiao Weihua; Dhananjaya V Kalvakolanu
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

10.  DNA methylation represses IFN-gamma-induced and signal transducer and activator of transcription 1-mediated IFN regulatory factor 8 activation in colon carcinoma cells.

Authors:  Jon M McGough; Dafeng Yang; Shuang Huang; David Georgi; Stephen M Hewitt; Christoph Röcken; Marc Tänzer; Matthias P A Ebert; Kebin Liu
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.